权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tobacco Craving in Smokers with Schizophrenia

精神分裂症吸烟者对烟草的渴望

基本信息

批准号：
8650804
负责人：
HEIDI J WEHRING
金额：
$ 17.4万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-15 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8650804
关键词：
Abstinence Alcohol or Other Drugs use Antibiotics Antismoking Award Biometry Carbon Monoxide Characteristics Cigarette Clinical Trials Cotinine Cues Data Data Analyses Development Diagnosis Disease Effectiveness Emotional Emotions Environment Environmental Impact Exhibits Fostering Future General Population Goals Intake Intervention K-Series Research Career Programs Measurement Measures Mental disorders Mentored Patient-Oriented Research Career Development Award Mentors Minocycline Mission Moods Morbidity - disease rate National Institute of Drug Abuse Nicotine Nicotine Withdrawal Nitric Oxide Patient Self-Report Persons Pharmaceutical Preparations Pharmacology Physiological Pilot Projects Placebos Play Population Principal Investigator Psyche structure Public Health Publishing Reporting Research Research Design Research Personnel Research Proposals Research Support Research Training Rewards Risk Role Safety Sampling Schizophrenia Smoke Smoker Smoking Smoking Behavior Smoking Cessation Intervention Strategic Planning Substance Addiction Substance Use Disorder Substance abuse problem Substance of Abuse Techniques Testing Time Tobacco Tobacco Dependence Training United States National Institutes of Health Urine Work attenuation base career cigarette smoking craving dual diagnosis effective intervention experience improved innovation mortality novel novel strategies programs public health relevance response severe mental illness skills smoking cessation smoking prevalence smoking relapse social substance abuse treatment treatment trial virtual reality

项目摘要

DESCRIPTION (provided by applicant): Cigarette smoking continues to have a major impact on morbidity and mortality, despite attempts to educate smokers and to improve smoking cessation interventions. Persons with schizophrenia are at greater risk for deleterious effects than the general population, due to the large percentage of persons with schizophrenia (60%-70%) who smoke cigarettes. This subset of the population are more likely to be heavier smokers, are three times more likely to start and five times less likely to quit smoking than people in the general population. Craving is a significant barrier to cessation, and may be experienced differently by persons with schizophrenia compared to the general population. This K23 mentored-research patient oriented career development award, submitted by Principal Investigator Dr. Heidi Wehring, focuses on craving and testing a novel craving intervention for smokers with schizophrenia. This focus fits well within the NIDA 5-Year Strategic Plan regarding substance abuse and treatment in persons with co-occurring mental disorders, and is consistent with the NIH mission to foster discoveries, innovative research strategies, and their applications by supporting research in the understanding of mental, addictive, and physical disorders. Dr. Wehring has a long-term career goal of becoming an independent investigator of treatment research for persons with schizophrenia who are dually diagnosed with a substance use disorder, specifically to determine novel approaches to the challenge of nicotine cessation. This may be done through using research to better define craving, abstinence, and other factors that may be targeted by pharmacological or nonpharmacological interventions. This K23 proposal has both research and training aims and goals. Short-term goals include contributions to the field of craving research in schizophrenia and Dr. Wehring's development as an independent investigator. These goals will be accomplished by a research proposal aiming to further define components of tobacco craving in smokers with schizophrenia, to determine the effects of minocycline on cigarette craving and smoking intensity via a pilot study, and to determine the relationship between changes in craving, smoking intensity, and responses to individualized cues/triggers to craving in smokers with schizophrenia. Dr. Wehring will be mentored by Dr. Deanna Kelly, an expert in schizophrenia, clinical trials, and dual diagnosis, and Dr. Stephen Heishman, an expert in tobacco, nicotine pharmacology, and cue-elicited craving, and will benefit from the support of Consultants Dr. Robert McMahon, an expert in biostatistics and research design and A. Eden Evins, with expertise in nicotine use in schizophrenia. Dr. Wehring will also pursue coursework during the K award period to increase skills and develop expertise necessary to become an independent investigator. This project will provide pilot data to build future research focusing on the development of interventions for smoking cessation in persons with schizophrenia. This is of paramount importance, as the understanding of underlying aspects of substance use will be instrumental in creation of effective interventions.

描述（由申请人提供）：尽管尝试教育吸烟者并改善戒烟干预措施，但吸烟仍对发病率和死亡率产生重大影响。精神分裂症患者比一般人群更容易受到有害影响，因为精神分裂症患者吸烟的比例很高（60%-70%）。这部分人群更有可能是重度吸烟者，开始吸烟的可能性是普通人群的三倍，戒烟的可能性是普通人群的五倍。渴望是戒烟的一个重要障碍，与一般人群相比，精神分裂症患者的经历可能有所不同。由首席研究员Heidi Wehring博士提交的K23指导研究患者导向职业发展奖，重点关注渴望和测试精神分裂症吸烟者的新型渴望干预。这一重点完全符合NIDA 5年战略计划中关于药物滥用和治疗的人与共同发生的精神障碍，并符合美国国立卫生研究院的使命，以促进发现，创新的研究策略，并通过支持在精神，成瘾和身体疾病的理解研究，其应用。Wehring博士有一个长期的职业目标，即成为一名独立的精神分裂症患者治疗研究的研究者，这些患者被双重诊断患有物质使用障碍，特别是为了确定应对尼古丁戒烟挑战的新方法。这可以通过使用研究来更好地定义渴望，禁欲和其他可能被药物或非药物干预所针对的因素来完成。这一K23提案既有研究目的，也有培训目的和目标。短期目标包括对精神分裂症渴望研究领域的贡献，以及Wehring博士作为独立研究者的发展。这些目标将通过一项研究提案来实现，该研究提案旨在进一步定义精神分裂症吸烟者烟草渴望的组成部分，通过一项试点研究确定米诺环素对吸烟渴望和吸烟强度的影响，并确定精神分裂症吸烟者渴望变化、吸烟强度和对个体化线索/触发因素的反应之间的关系。Wehring博士将由精神分裂症、临床试验和双重诊断专家Deanna Kelly博士和烟草、尼古丁药理学和线索诱发渴望专家Stephen Heishman博士指导，并将受益于生物统计学和研究设计专家Robert McMahon博士和A.伊登·埃文斯，在精神分裂症中尼古丁使用方面的专家。Wehring博士还将在K奖期间继续学习课程，以提高技能并发展成为独立调查员所需的专业知识。该项目将提供试点数据，以建立未来的研究，重点是制定精神分裂症患者戒烟的干预措施。这一点至关重要，因为了解药物使用的基本方面将有助于制定有效的干预措施。